Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
- PMID: 32527866
- DOI: 10.1136/annrheumdis-2020-217806
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
Keywords: antirheumatic agents; arthritis, psoriatic; biological therapy; tumour necrosis factor inhibitors.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al.Ann Rheum Dis. 2021 Apr;80(4):e47. doi: 10.1136/annrheumdis-2020-217953. Epub 2020 Jun 11. Ann Rheum Dis. 2021. PMID: 32527864 No abstract available.
-
Response to: 'Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?' by Akpabio et al.Ann Rheum Dis. 2022 Aug;81(8):e143. doi: 10.1136/annrheumdis-2020-218472. Epub 2020 Jul 28. Ann Rheum Dis. 2022. PMID: 32723750 No abstract available.
-
Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?Ann Rheum Dis. 2022 Aug;81(8):e142. doi: 10.1136/annrheumdis-2020-218449. Epub 2020 Jul 28. Ann Rheum Dis. 2022. PMID: 32723751 No abstract available.
Comment on
-
Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India.Ann Rheum Dis. 2021 Jan;80(1):e1. doi: 10.1136/annrheumdis-2020-217509. Epub 2020 Apr 16. Ann Rheum Dis. 2021. PMID: 32299795 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical